| INTRODUCTION
Coeliac disease (CD) is a chronic, immune-mediated, systemic disorder elicited by the ingestion of gluten in genetically predisposed individuals and affecting primarily the small bowel. 1 The most common skin phenomenon of CD is dermatitis herpetiformis (DH), which was first considered to be a skin disease occurring concomitantly with CD, but is nowadays considered as a specific manifestation of the coeliac spectrum. 2, 3 A small-bowel mucosal lesion is present in three-fourth of the DH patients. 3, 4 The treatment of CD and DH is a strict, lifelong, gluten-free diet (GFD), ie permanent avoidance of products containing wheat, rye and barley. Most CD and DH patients respond to GFD with a resolution of symptoms and improvement of the villous morphology in the small bowel. 1, 5, 6 When skin lesions are severe or their response to GFD is slow, DH patients may initially receive additional treatment with the anti-inflammatory drug dapsone. 5 There is marked geographical variation in national CD incidences and temporal trends in the frequencies of CD. 7, 8 According to most reports, the incidence of CD has dramatically increased over the past decades, especially in children and in Western Europe. 7, 8 Regarding adults, we found 11 follow-up studies on temporal changes in the incidence of diagnosed CD.
Some of these studies are nationwide, while many were local. An increasing incidence was reported in Olmsted County, Minnesota, USA during the period of 1950-2001, 9 in India, on the local level, during 1995-2000, 10 among US military personnel during 1999-2008, 11 in the Netherlands during 1995-2010 12 and in the UK during the years 1990-2011. 13 15, 16 showed an increasing trend in CD incidence. A report from Denmark has described a stable incidence during 1976-1991, 17 as well as another from Italy, in the Terni area during 2000-2010. 18 One study from Olmsted County, Minnesota, USA discovered that the incidence increased between 2000 and 2004 and thereafter levelled off by 2010. 19 To the best of our knowledge, no one has reported a decreasing trend in the incidence of CD in adults during the 2000s-with the exception of a decrease in the incidence of DH. 13, 20 Thus, the existing studies regarding current trends in the incidences of CD do not all agree with one another and may reflect geographical differences. We used the opportunity to study nationwide data from well-defined registries in Finland to gain a thorough estimate of the temporal changes in the incidences of biopsy-verified CD and DH among adults, over a recent 10-year period. We also assessed whether there were any gender, age or region-related differences in the temporal changes of the incidences. Our hypothesis was that the total incidence of CD in Finnish adults has levelled off since the millennium. This is based on the high general awareness of CD in Finland and active case determination over a period of more than 2 decades. 
| Identification of the onset of disease
To receive the reimbursement for GFD, the applicant must attest the The quality of the standard operating procedure for small-bowel biopsies for CD diagnosis in Finland was recently shown to be high and reliable. 25 Before the reimbursement can be granted, a medical examiner at the local SII office checks whether or not the diagnostic investigations described in the certificate fulfil the criteria for a CD diagnosis. The entire administrative process, from providing the certificate to the final decision by the SII, generally takes only a couple of weeks. Thus, the date (month and year) when the decision concerning the dietary grant took effect was used as a proxy indicator for the date of diagnosis. Also, we ensured that the CD cases among our cohort were accurately defined as incident by checking back through the registry data and excluding patients with a previous entitlement to this reimbursement. In addition to approved cases, the database also contains data on rejected dietary grant applications, and we depicted the rejection rates during the study period as well.
| Statistical methods
The annual incidence rates per 100 000 at-risk adults were calculated by dividing both the number of newly diagnosed total CD (CD + DH) cases and DH cases by the total population (20-79 years of age) during each calendar year between 2005 and 2014. The differences in the mean age of diagnosis between each diagnostic period (2-year periods were used to diminish annual random variation) were tested by an analysis of variance.
Poisson regression models, with the number of new cases as the response variable and log e at-risk person years as the offset, were used to calculate the estimates for the incidence rates and incidence rate ratios (IRRs) with 95% confidence intervals (95% CI). The patient's gender, age and region of residence at diagnosis, and the calendar year of diagnosis, were included in the models as covariates. Based on the agespecific total incidences of CD, the age at diagnosis was categorised into 2 groups: 20-34 years of age (young adults) and 35-79 years of age (middle-and old-age people). This categorisation was selected after visual inspection of the observed incidence rates (Figure 2A ,B, see also Section 3). Due to significant third-degree interaction (gender 9 age group 9 year of diagnosis, P < .001), the temporal changes Oulu University Hospital districts). Confidence intervals in multiple comparisons were Bonferroni corrected. As sensitivity analyses, the application rates and application rate ratios (ARRs) were analysed using similar models as used for the newly diagnosed total CD cases.
The temporal changes in the incidence of total CD cases and DH cases, separately within the age groups, were estimated using Poisson regression models in the following 2 ways: (1) The magnitude of change in the incidence rates during the overall 10-year observation period was quantified by extreme periodical IRRs with 95% CIs between the first and last 2-year periods; (2) The trends of change in the total incidence rate during all of the observation years. The linearity of the trends was first checked using models that included age at diagnosis and the observation time (years 2005-2014) split into 2-year (Table S1 ; unadjusted IRRs) and 5-year sub-periods (data not shown), and modelled as a categorical predictor. While the rate of change was steady throughout the study period and the interaction terms (for year of diagnosis 9 sub-periods) were nonsignificant, the trends were estimated based on the linear slopes of the incidence rates in the models that utilised the year of CD diagnosis as a continuous predictor. Analyses were done using the SAS 9.4 software (SAS Institute, Inc., Cary, NC, USA).
| Ethical considerations
The data permit was admitted by the SII. In accordance with Finnish legislation, no approval by an ethical committee or informed consent is required for registry-based studies done without contacting the study subjects. mean annual incidence rate of 31 per 100 000 (95% CI 30-32). The crude total incidence was 33 per 100 000. The stratified 2-year calendar period incidence rates of CD by 5-year age groups and gender are shown in Figure 2A ,B and Table S1 .
| RESULTS
Most patients (62.1%) were female. The mean annual incidence of CD among women during the study period was nearly twice as high as among men, 42 vs 22 per 100 000 respectively (IRR 1.90, 95% CI 1.81-1.99; P < .001). The incidence rates of CD increased with age, especially among men (age 9 sex interaction P < .001; age main effect P = .001 and P = .225 for men and women, respectively (Figure 2A,B) . However, women were nearly 30 years younger than men during the peak annual incidence of CD (Figure 2A,B) . The mean (SD) age at diagnosis of adult CD was 48.0 (15.6) years and 51.4 (14.6) years for women and men, respectively (P < .001).
Between Throughout the 10-year observation period, the average rate of decrease in the total incidence of CD was 3.3% per year (95% CI 2.7-3.9; P for trend <.001). For women aged 35-79 years, the decline in the annual incidence was highly significant, 4.8% per year and for men of the same age, 3.0% per year (Table 2 ). For young adults under 35 years of age, the annual decrease was nonsignificant, 0.2% and 0.5% for women and men, respectively. In the geographical division, the decline in the annual incidence was highly significant in all 3 regions for the older group, aged 35-79, whereas for the young adults, the annual changes by these 3 regions were nonsignificant.
3.1 | Sub-analysis of DH (diagnosis code L13, or dietary grant for K90 and purchases of dapsone)
At least 540 cases (4.2%) were interpreted as having DH: 389 (3.0%)
cases with diagnosis code L13, and 157 (1.2%) cases with the diagnosis K90 and drug purchases of dapsone). Thus, the annual incidence of DH was 1.2/100 000 (95% CI 1.3-1.5) (the crude incidence 1.4), and the incidence was almost identical between gender (adjusted gender IRR 1.00). Throughout the 10-year observation period, the average rate of decline in the incidence of DH at 35-79 years of age was 3.8% (95% CI 1.2-6.7; P = .016) per year, whereas for those younger than 35 years of age, the change of 2.8% was nonsignificant.
| Sensitivity analyses
Throughout the 10-year observation period, the nationwide applica- 0.84-0.97; P = .005). The average rate of decrease in the application rate for the dietary grant was 2.8% per year (95% CI 2.2-3.4; P for linear trend <.001). Thus, the temporal changes in the total application rate for the dietary grant were almost parallel with our main result for incidence rates of total CD, ie rates for accepted applications (Tables 1 and 2 ).
The SII is constantly striving for uniformity in decision practices across Finland. We noticed that the rejection rate for the dietary grant was 6.2% (n = 854) between the years 2005 and 2014, and the mean (SD) age of rejected applicants was 49.1 (16.7) years (68.4% female). Of all applicants for the dietary grant, 6.8% females and 5.3% males were rejected (P < .001). However, the rejection rate was higher among young adults, 7.4% compared to 5.9% among applicants older than 34 years of age (P = .006). The rejection rate was also significantly higher (P < .001) in densely populated Southern Finland (7.4%) as compared to sparsely populated Northern Finland (4.4%). During the whole period of observation, the rejection rate increased gradually over time: for those applicants between the ages of 35-79 years, the rejection rate was 4. There was still a significant declining trend of incidence among persons aged 35-79 years at the onset of CD (data not shown). Thus, the gradually increasing rejection rate did not essentially affect our major temporal finding: a decreasing incidence of total CD among those who were 35-79 years of age.
| DISCUSSION
In this nationwide, population-based registry study in adults, we show that the total incidence of biopsy-verified CD declined from T A B L E 1 Incidence rate ratios (IRR) of adult onset total coeliac disease (dermatitis herpetiformis included) and application rate ratios (ARR) of the dietary grant with 95% confidence intervals (95% CI) in periods 2013-2014 vs [2005] [2006] Table S1 ). The values were calculated per 100 000 person-y and the 95% confidence intervals using Poisson regression model VIRTA ET AL.
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2005 to 2014 in middle-and old-age people in Finland, in women especially. At the same time, the incidence of DH decreased among this age group as well. In young adults, the incidence of total CD (and DH) remained stable during the observation period. For the first time, our results confirmed a declining trend in the incidence of CD among adults.
Reported incidences of CD originate mostly from Western Europe and vary from 1.3 to 39/100 000/year for adults. 12, 13, [15] [16] [17] 26 Finland has reported one of the highest nationwide incidence rates of total CD, 39 per 100 000 in 2004 . 26 In the present study, we assessed the incidence rate of total CD based on biopsy-verified cases and observed a decline of 13% from 33 per 100 000 during the years 2005-2006 to 29 per 100 000 during 2013-2014 (adjusted IR). Many researchers agree that for every patient currently diagnosed with CD, there remain several undiagnosed individuals. 27 The awareness of CD varies among countries and has, in general, been poor, eg among primary care practitioners in North America as late as the beginning of the millennium. 9 In Finland, however, the clinical detection rate of CD has been especially high due to an active case determination policy for the disease during the past decades, achieved through the education of the health care staff and the advocation of serological screening among at-risk groups. 21 It was assumed that this active diagnostic approach led to a steady, almost 10-fold increase (from 3 to almost 30 per 100 000) in the number of newly diagnosed cases of CD in Finland during 1980-2003. 21 The indirect evidence for a true increase of incidence of CD is based on the data of antibody screening of historical, stored sera from the general population. This showed that the frequency of . 11 This was in contrast to our finding of a respective decrease among this age group.
The development of the observer-independent methodology for the detection of tissue transglutaminase (tTG) antibodies has enabled screening for CD at a low cost. 29, 30 Thus, risk groups, eg family members, can easily be screened for the disease in line with patients presenting minor gastrointestinal or other disease related symptoms.
Indeed, there is some current evidence that newly diagnosed patients present with minor symptoms as compared to the cases diagnosed during the era when only less specific screening was available (gliadin antibody tests). 31, 32 Also, a substantial proportion of CD diagnoses represent persons screened during primary health care examinations. CD may develop at any age, but a delay in diagnosis for several years is common. In adults, on average, the delay is still 4-13 years. [33] [34] [35] [36] [37] In an adult cohort from the UK, the age at the diagnosis of CD made a shift of 6 years towards younger age between 1960-1964 and 1975-1979 , along with an increasing incidence. 38 Our results parallel this observation; the mean age at diagnosis of adults fell by 1.4 year during our 10-year observation period, and the incidence of CD declined. Meanwhile, the population structure showed a change towards ageing in our general population (an average of 1 year during the past decade). When the diagnosis of CD is made at an earlier age, it is evident that the number of new cases in older age groups will decrease in time, if age, as such, does not affect the risk for the disease. Thus, the minor changes in population T A B L E 2 Time trends for annual change with 95% confidence intervals (95% CI) for the incidence (= grant) rate of and application rate of the dietary grant during the years [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] Regional slope estimates combined for age groups.
structure do not solely explain the decrease in the incidence of CD among those aged 35-79 years.
Our data on biopsy-verified CD cases were based on a national registry listing dietary grants entitled by SII to all patients with CD and DH regardless of their socioeconomic status. The dietary grant has no limitations regarding use (and not subjected to tax), and thus, we assume that only a few diseased subjects fail to apply for the compensation. One strength of this registry-based data is the reliability of the diagnoses, as a small-bowel or skin biopsy that fulfils the diagnostic criteria of CD or DH is mandatory to receive the grant. 1, 23, 39 The validity of the registry is also high. 21 The diagnostics of CD in the Finnish public health service and the nationwide practice for entitlement to the dietary grant provided by SII was stable during the study period.
Unexpectedly, we observed an increase in the rejection rate of applications for the dietary grant. At the end of the study period, the rejection rate was close to 8% for those applicants aged 35-79 years. It may well be that most of the rejected certificates did not list biopsyverified findings, but rather only high levels of tTG antibodies, which are suggestive of the disease. 40 A few years ago, ESPGHAN (European Society of Pediatric Gastroenterology, Hepatology and Nutrition) published new guidelines for the diagnosis of CD with an option to determine the diagnosis in patients with high levels of antibodies (>10 times the upper limit of normal) and HLA, as compatible to CD, with no need to take a confirmatory biopsy. 1 Thus, it is possible that such criteria had been adopted by some physicians providing the certificates, but as the SII did not change its policy during the study period, the dietary grant was granted only to patients with biopsy-verified diagnosis. This is strengthened by a previous study reporting that the most common reason (42%) for the rejection of a dietary grant application was a normal small-bowel biopsy, as one-third of such patients consume a GFD already before their biopsy was taken. 24 However, if we assume that the rejection rate was stable over the whole study period and consider the rejected CD cases as true incident cases, our findings of a decrease in the incidence of CD would not change significantly. In other words, the decreasing trends of adult CD incidence could not be explained by concurrent increases in rejection rates for the dietary grant.
As the aetiology of CD appears to be multifactorial, a significant aspect of pathogenesis is attributed to genetic predisposition. However, the impact of altered genetics in disease trends in a population occurs slowly and thus, does not explain the observed rapid changes in the incidences of CD. More likely, environmental or lifestyle factors are responsible for such temporal changes. The observed decline in the incidence levels suggests that, for CD (including DH), the triggers, though yet unidentified, have disappeared, their virulence has lessened, or individuals have gained resistance against them. Intriguingly, the consumption of wheat, rye and barley in the diet has markedly decreased in Finland during the past decades, and the annual consumption of wheat has continuously decreased also during our 10-year study period from an average of 49 kg per person to 46 kg per person, 41 which signifies less exposure to gluten.
The search for triggering factors of gluten-induced villous atrophy has been active but no definite clues have been found. Enteropathogenic viruses have been suggested as candidates for environmental triggers, mostly because they seem to play an important role in the pathogenesis of type 1 diabetes, a disease frequently presenting with CD. 42 Vitamin D intake is another debated environmental factor in the pathogenesis of autoimmune diseases, and low levels have been assumed to play a role in the development of eg type 1 diabetes and inflammatory bowel disease 43, 44 and CD, although the latter finding is inconsistent. 45, 46 Vitamin D levels are somewhat lower in populations living in the north, which is attributed to less exposure to sunlight (as vitamin D3 is mainly biosynthesised from 7-dehydrocholesterol in skin exposed to ultraviolet light).
Interestingly, we detected a North-South gradient in the incidence of CD. The northern areas presented a higher incidence. Whether this difference is partly attributed to lower levels of vitamin D in the northern population remains unanswered, as the observed differences in the vitamin D levels and total exposure to sun are minor. 44 Unfortunately, the registry we used for case detection does not include any data related to vitamin levels or environmental factors.
In most reports, the proportion of DH among CD patients has an average of about 10%, 9, 13, 21, 36 whereas, in our data, only 3% were diagnosed with DH. One limitation of our approach is that the stratification of CD cases (diagnosis code K90) and DH cases (code L13)
is not reliably documented in the Dietary Grant Registry maintained by the SII. Therefore, we also used data from the Drug Purchase
Registry, which revealed that 1.2% of CD cases with a diagnosis code of K90 in the dietary grant registry could be interpreted as DH cases due to purchases of dapsone. Combining data from these 2 data sources (Dietary Grant Registry and Drug Purchase Registry) yielded a mean annual incidence of DH of 1.2/100 000 (adjusted incidence; crude incidence 1.4). This incidence is equivalent to the figure reported from the UK between 1990 and 2014. 13 Comparable to total CD, the incidence of DH at 35-79 years of age decreased throughout the study period with an average annual decrease of 3.8%. Unlike with CD, the incidence of DH was identical between genders (IRR 1.00). In our study, the dropping rate of total incidence of CD at 35-79 years of age was not due to a decreasing incidence of DH, as DH cases comprise only a marginal proportion of total CD.
Taken together, we report a decrease in the incidence of CD (including DH) in middle-and old-aged adults, based on nationwide registry data in a country that has advocated case determination for more than 2 decades. This suggests that the exposure to triggering factors for CD, although yet unidentified, has lessened among the adult population in Finland.
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